Fast bleed control—because stopping bleeds quickly is important.

The faster you can infuse treatment, the sooner it can start to work. NovoSeven® RT is quick to mix and fast to infuse.

Fast bleed control—because stopping bleeds quickly is important.

Proven to be effective.

The effectiveness of NovoSeven® RT in controlling bleeds has been well studied—with more than 70 trials and registries completed.

Data from a randomized, double-blind study of patients with hemophilia A and B with and without inhibitors.

Also proven effective in the adept™2 study, one of the largest clinical trials conducted in patients with hemophilia with inhibitors.


Room temperature stable and travel ready.

NovoSeven® RT comes in compact packaging, and is room temperature stable up to 77°F, so you can be on the go.

For complete storage information, please see Prescribing Information.


Quick to mix.a

NovoSeven® RT with MixPro® makes mixing a dose fast. The prefilled syringe means no extra steps to fill a syringe with diluent.
 

After mixing, NovoSeven® RT may be stored at room temperature in the vial for up to 3 hours.

aCompared to mixing using histidine vials.


Fast to infuse.

Faster infusion means NovoSeven® RT gets to work stopping bleeds more quickly.
 

  • NovoSeven® RT is up to 18x faster to infuse than FEIBAb,c
  • Infusing takes 2 to 5 minutes

bIndividual doses are compared and based on an 88-kg (194-lb) person receiving a single dose for a joint bleed (NovoSeven® RT: 90 mcg/kg; FEIBA: 70 U/kg).
cPatients are cautioned that the maximum injection or infusion rate must not exceed 2 units per kilogram of body weight per minute.

 


Fast bleed control.

Helps control joint bleeds in as few as 5 hours with a median of 2 doses.d
 

dBased on individual dosage for joint bleeds in people with hemophilia A or B with and without inhibitors.


Recombinant safety and a low rate of blood clots.

NovoSeven® RT is made without any human blood or plasma. It is the only FDA-approved recombinant bypassing agent for hemophilia with inhibitors. Recombinant manufacturing minimizes the possibility of viral contamination. And, clinical trials showed adverse events (blood clots) occurred in 0.2% of bleeding episodes.e

eIn people with congenital hemophilia.

What if I need surgery or a procedure?

We understand that you have concerns about controlling bleeds if you ever need surgery or a procedure. The good news is that NovoSeven® RT is approved by the FDA for treating people with hemophilia A or B with inhibitors during and after surgery and procedures.

In fact, in a clinical trial, NovoSeven® RT was proven to effectively control bleeds throughout the surgical process. Here are the results:

Talk with your doctor for more information on controlling bleeds during and after surgery or procedures.

What about surgery and procedures?

Approved for surgical use and procedures for patients with hemophilia A or B with inhibitors.

Hear a patient's story.

Meet Justin. NovoSeven® RT fits in when he's living life on the go.

Hear from people who

share your experience.


New to treatment? It’s

easy to get started.


Recombinant manufacturing

minimizes viral

contamination.

Selected Important Safety Information

WARNING: BLOOD CLOTS

  • Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported.
  • Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function.
  • Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT.

Indications and Usage

NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) is used for:

  • Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and people with Glanzmann’s thrombasthenia who have a decreased or absent response to platelet transfusions
  • Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia

Important Safety Information

WARNING: BLOOD CLOTS

  • Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported.
  • Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function.
  • Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT.

Warnings and Precautions

  • NovoSeven® RT should be used with caution if you have an increased risk for blood clots, such as with disseminated intravascular coagulation (DIC), clogged arteries, crush injury, septicemia (an infection in the blood), uncontrolled bleeding after giving birth, history of heart disease, liver disease, limited movement following surgery, in elderly people, in newborns, or if you are taking aPCCs/PCCs (activated or nonactivated prothrombin complex concentrates) with NovoSeven® RT.
  • Allergic reactions, including serious whole body allergic reactions, have been reported with NovoSeven® RT. Tell your healthcare provider if you are allergic to NovoSeven® RT, any of its ingredients, or mice, hamsters, or cows. If you think you are having an allergic reaction, call your healthcare provider right away. Some signs of allergic reaction may include shortness of breath, rash, itching, redness of the skin, and fainting/dizziness.
  • People with Factor VII deficiency should be monitored by their healthcare provider for antibodies, which can cause NovoSeven® RT to stop working properly.

Side Effects

  • The most common and serious side effects are blood clots.
  • Tell your healthcare provider about any side effects that bother you or do not go away.

Use with Other Drugs

  • Blood clots may occur if NovoSeven® RT is given with Coagulation Factor XIII (13).

Please click here for Prescribing Information.

NovoSeven® RT is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.